Background. Acute lymphoblastic leukemia (ALL) represents the most common cause of childhood cancer, accounting for 25% of all malignancies. Overall survival has improved remarkably due to the better understanding of its pathophysiology, the creation of new chemotherapy regimes and the improvement of the supportive care and the management of the disease complications as well as to complications secondary to treatment.